Today announced the signing of a license contract with CJ CheilJedang Co.

, granting CJ distinctive rights to develop, manufacture and commercialize RaQualia’s 5-HT4 Partial Agonist in Korea, China, Taiwan, Southeast and India Asia. Under the conditions of the contract, RaQualia will receive an upfront payment from CJ and is certainly permitted receive development milestones and royalties on sales of products commercialized beneath the permit. RaQualia and CJ signed a Memorandum of Understanding in June 2010 to establish a strategic alliance in innovative gastrointestinal therapies. This is actually the 2nd license contract between RaQualia and CJ following license contract for Acid Pump Antagonist in September 2010..Researchers found 101 individuals had stage I colon cancer, 105 patients were identified as having Stage II colon cancer, 72 with Stage III, and 61 patients had stage IV cancer of the colon. The survival rates of most patients were evaluated from enough time of initial colon cancer diagnosis. After a two. 5 year follow-up, researchers found asymptomatic patients had considerably improved survival in comparison to symptomatic patients. There was a sustained difference in stage of disease favoring patients who were asymptomatic, for all ages between 50 and 84, suggesting a role pertaining to preventive screening among individuals of advancing age even. According to Dr.. BUSM’s medical education plan wins HIDTA award for Outstanding Avoidance Effort White House Medication Control Plan Director Michael Botticelli has awarded Boston University College of Medication's Safe and sound and Competent Opioid Prescribing Education plan a 2014 National Large Intensity Drug Trafficking Region award for Outstanding Avoidance Effort.